Cahill Thomas 4

What Happened

• Thomas Cahill, a director of Prime Medicine, received a derivative award covering 75,000 shares on June 5, 2026. The grant is reported at $0.00 (no cash paid at grant), and is recorded as an award/other acquisition rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-05; Filing date: 2026-06-08.
• Transaction type: Award/Grant (derivative); Shares involved: 75,000; Reported price: $0.00.
• Shares owned following the transaction: not specified in the provided filing excerpt.
• Footnote: The award vests in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to Cahill’s continuous service through the vesting date.
• The filing shows the grant; there is no indication in the excerpt that the report was marked late.

Context

• This was a director compensation award (derivative grant), not a purchase or immediate sale of shares. Such grants are commonly used to align directors with shareholder interests; they only convert into owned shares if and when they vest or are exercised per the award terms.